Navigation Links
Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports

New York, NY (PRWEB) July 27, 2014

A consolidated litigation that now includes more than 600 Risperdal lawsuit ( filings is proceeding in the Philadelphia Court of Common Pleas, where a meeting has been scheduled in August to discuss claims involving the antipsychotic medication, Bernstein Liebhard LLP reports.

A Calendar updated on the court’s website indicates that the meeting will take place on August 6, 2014 at 11:00 a.m. At this time, parties in the litigation will likely address issues related to Risperdal lawsuits, which similarly accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc. of failing to adequately warn about injuries that allegedly stem from use of the drug. According to court documents, these may include complications associated with gynecomastia, a condition referring to male breast development. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm continues to hear from men and young boys who allegedly developed gynecomastia after taking Risperdal. We are pleased to see further progress in the Pennsylvania litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who were allegedly injured by Risperdal.

Risperdal Lawsuits
According to court records, Risperdal lawsuits filed in the Philadelphia Court of Common Pleas similarly allege that the medication, which is approved by the U.S. Food and Drug Administration (FDA) to treat such conditions as schizophrenia and bipolar disorder, may cause a series of painful and embarrassing side effects. Included in this litigation are hundreds of claims that Risperdal may stimulate production of prolactin, a hormone associated with female breast development and lactation. This may increase a man’s risk of developing breasts, which can necessitate liposuction and mastectomy procedures to reverse the complication, Risperdal plaintiffs allege.

Johnson & Johnson and Janssen have also been accused of promoting the drug off-label to children, before it garnered FDA approval for pediatric uses in 2006. The companies were also aware of Risperdal gynecomastia and other side effects associated with the medication that they concealed from the general public, according to claims.

Court records indicate that these allegations were shared by the U.S. Department of Justice, who filed charges against Johnson & Johnson and Janssen last year over its marketing of Risperdal and certain other drugs. In November 2013, the federal government announced that the companies paid $2.2 billion to resolve criminal and civil charges that Risperdal was improperly marketed for pediatric uses, and may have concealed its association with elevated levels of prolactin, a side effect suggested to cause male breasts.

Men and young boys who allegedly developed gynecomastia after taking Risperdal may be eligible to pursue a lawsuit against Johnson & Johnson and Janssen. Learn more about the process of filing a Risperdal lawsuit when you visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports
2. New Risperdal Lawsuit Website Published by Bernstein Liebhard LLP; Provides Side Effect Information, Litigation Updates
3. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes New Report Detailing Increasing Use of Risperdal and other Antipsychotic Drugs Among Children
4. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
5. Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies
6. As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
7. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
8. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
9. As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Launches Website to Provide Information Regarding Alleged Association Between Risperdal and Gynecomastia
10. Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
(Date:11/27/2015)... ... , ... According to an article published November 13th on, ... D.C. revolved around the fact that proper dental care, both at-home and in the ... between periodontal disease (more commonly referred to as gum disease) and diabetes. According to ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, ... in light of the recent terrorist attacks in Paris, other cities are taking extra ... from reaching U.S. soil. Especially around special events that may be high-profile in nature, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A team ... ways to treat it. Surviving Mesothelioma has just posted the findings on the ... University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I ... an inventor from Hillside, N.J. "Many people catch diseases simply from sitting on ... will always be protected from germs." , He developed the patent-pending QUDRATECS to ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
Breaking Medicine Technology: